Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anflekitug - Sunshine Guojian Pharmaceutical

Next Previous
Drug Profile

Anflekitug - Sunshine Guojian Pharmaceutical

Alternative Names: 613; Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection - Sunshine Guojian Pharmaceutical; SSGJ-613; SSGJ-613 100mg; Yisaina

Latest Information Update: 27 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sunshine Guojian Pharmaceutical
  • Class Antigouts; Antipyretics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 1beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gouty arthritis
  • Phase I/II Gout
  • Discontinued Fever; Juvenile rheumatoid arthritis

Most Recent Events

  • 21 Aug 2026 Launched for Gouty arthritis in China (SC) before August 2026
  • 21 Aug 2026 Registered for Gouty arthritis in China (SC)
  • 20 Jul 2026 Sunshine Guojian Pharmaceutical plans phase II trial in Gouty-arthritis in August 2026 (SC) (NCT07708181)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top